Strategies for overcoming ABC-transporters-mediated multidrug resistance [MDR] of tumor cells

• Autorzy: Borowski E. , Bontemps-Gracz M.M. , Piwkowska A.
• Języki publikacji: EN

Abstrakty

EN

The development of multidrug resistance (MDR) of tumors is a major cause of failure in antitumor chemotherapy. This type of crossresistance is due to the expression of ABC transporter glycoproteins actively effluxing the drug from the cells against the concentration gradient at the expense of metabolic energy, thus preventing the accumulation in cells of therapeutic concentration of active agents. In this review strategies for overcoming this adverse phenomenon are discussed. They comprise the control of expression of MDR glycoprotein transporters and control of the functioning of the expressed transporter proteins. The latter approach is discussed in more detail, comprising the following general strategies: (i) development of compounds that are not substrates of efflux pump(s), (ii) use of agents that inactivate (inhibit) MDR proteins, (iii) design of cytostatics characterized by fast cellular uptake, surpassing their mediated efflux, (iv) use of compounds competing with the drug for the MDR protein-mediated efflux. Positive and negative aspects of these strategies are analysed, with special attention put on strategy based on the use of MDR modulators in combination therapy, allowing the restoration of cytotoxic activity of clinical cytostatics towards resistant tumor cells.

Słowa kluczowe

EN

multidrug resistance; chemotherapy; tumour cell; modulator; antitumour cytostatic drug; antitumour therapy; antimetabolite

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 3
• Opis fizyczny: p.609-627,fig.,ref.

Twórcy

autor

Borowski E.

• Gdansk University of Technology, Gdansk, Poland

autor

Bontemps-Gracz M.M.

autor

Piwkowska A.

Bibliografia

• Adams J (2002) Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 8: S49–S54.
• Aftab DT, Ballas LM, Loomis CR, Hait WN (1991) Structure- activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. Mol Pharmacol 40: 798–805.
• Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL (1998) Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther 286: 419–428.
• Al-Shawi MK, Senior AE (1993) Characterization of the adenosine triphosphatase activity of Chinese hamster Pglycoprotein. J Biol Chem 268: 4197–4206.
• Al-Shawi MK, Urbatsch IL, Senior AE (1994) Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 269: 8986–8992.
• Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89: 8472–8476.
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398.
• Antonini I, Cola D, Polucci P, Bontemps-Gracz M, Borowski E, Martelli S (1995) Synthesis of (dialkylamino)alkyldisubstituted pyrimido[5,6,1-de]acridines, a novel group of anticancer agents active on a multidrug resistant cell line. J Med Chem 38: 3282–3286.
• Antonini I, Polucci P, Cola D, Bontemps-Gracz M, Pescalli N, Menta E, Martelli S (1996) Pyrimido[4,5,6- kl]acridines, a new class of potential anticancer agents. Synthesis and biological evaluation. Anticancer Drug Des 11: 339–349.
• Antonini I, Polucci P, Kelland LR, Menta E, Pescalli N, Martelli S (1999a) 2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships. J Med Chem 42: 2535–2541.
• Antonini I, Polucci P, Martelli S (1999b) Pyrimido[4,5,6- kl]acridines. Synthesis, in vitro cytotoxicity and structure-activity relationships. Anticancer Drug Des 14: 451–459.
• Antonini I, Polucci P, Magnano A, Martelli S (2001) Synthesis, antitumor cytotoxicity, and DNA-binding of novel N-5,2-di(omega-aminoalkyl)-2,6-dihydropyrazolo[3,4,5-kl]acridine-5-carboxamides. J Med Chem 44: 3329–3333.
• Antonini I, Polucci P, Magnano A, Gatto B, Palumbo M, Menta E, Pescalli N, Martelli S (2002) 2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents. J Med Chem 45: 696–702.
• Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL (2000) Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 60: 83–90.
• Astriab-Fisher A, Ye D, Sergueev DS, Fisher MH, Shaw BR, Juliano RL (2002) Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J Biol Chem 277: 22980–22984.
• Astriab-Fisher A, Fisher MH, Juliano R, Herdewijn P (2004) Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochem Pharmacol 68: 403–407.
• Avendano C, Menendez JC (2002) Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9: 159–193.
• Azzaria M, Schurr E, Gros P (1989) Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 9: 5289–5297.
• Bartsevich VV, Juliano RL (2000) Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol Pharmacol 58: 1–10.
• Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T (2001) A Phase I study of infusional vinblastine in combination with the Pglycoprotein antagonist PSC 833 (valspodar). Cancer 92: 1577–1590.
• Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ (2001) Collateral sensitivity to gemcitabine (2’,2’-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 61: 1401–1408.
• Blagosklonny MV (1999) Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 13: 2031–2035.
• Blagosklonny MV (2001) Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 15: 936–941.
• Blagosklonny MV (2003) Targeting cancer cells by exploiting their resistance. Trends Mol Med 9: 307–312.
• Boer R, Dichtl M, Borchers C, Ulrich WR, Marecek JF, Prestwich GD, Glossmann H, Striessnig J (1996) Reversible labeling of a chemosensitizer binding domain of P-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35: 1387–1396.
• Boerner SA, Tourne ME, Kaufmann SH, Bible KC (2001) Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer 84: 1391–1396.
• Bontemps-Gracz M, Milewski S, Borowski E (1991) The influence of L-norvalyl-N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic acid, an antifungal agent, on mammalian cells in tissue culture. Acta Biochim Polon 38: 229–239.
• Bontemps-Gracz MM, Kupiec A, Antonini I, Borowski E (2002) The ability to overcome multidrug resistance of tumor cell lines by novel acridine cytostatics with condensed heterocyclic rings. Acta Biochim Polon 49: 87–92.
• Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295–1302.
• Castro AF, Horton JK, Vanoye CG, Altenberg GA (1999) Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol 58: 1723–1733.
• Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389.
• Choi CH, Kim JH, Kim SH (2004) Reversal of P-glycoprotein- mediated MDR by 5,7,3’,4’,5’-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 320: 672–679.
• Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR, Danishefsky SJ (1998) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 95: 15798–15802.
• Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654.
• Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95: 9831–9836.
• Conseil G, Perez-Victoria JM, Jault JM, Gamarro F, Goffeau A, Hofmann J, Di Pietro A (2001) Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 40: 2564–2571.
• Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32: 329–376.
• Cucco C, Calabretta B (1996) In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 56: 4332–4337.
• Dalton WS, Scheper RJ (1999) Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 91: 1604–1605.
• Dantzig AH, Law KL, Cao J, Starling JJ (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8: 39–50.
• Dantzig AH, de Alwis DP, Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55: 133–150.
• Dean M, Hamon Y, Chimini G (2001a) The human ATPbinding cassette (ABC) transporter superfamily. J Lipid Res 42: 1007–1017.
• Dean M, Rzhetsky A, Allikmets R (2001b) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156–1166.
• Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical druginteraction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94: 10594–10599.
• D’Incalci M (1998) Some hope from marine natural products. Ann Oncol 9: 937–938.
• Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665–15670.
• Dzieduszycka M, Martelli S, Arciemiuk M, Bontemps- Gracz MM, Kupiec A, Borowski E (2002) Effect of modification of 6-[(aminoalkyl)amino]-7H-benzo[e]-perimidin-7-ones on their cytotoxic activity toward sensitive and multidrug resistant tumor cell lines. Synthesis and biological evaluation. Bioorg Med Chem 10: 1025–1035.
• Dzieduszycka M, Bontemps-Gracz MM, Stefanska B, Martelli S, Piwkowska A, Arciemiuk M, Borowski E (2005) Synthesis of 7-oxo-7H-naphto[1,2,3-de]quinoline derivatives as potential anticancer agents active on multidrug resistant cell lines. Bioorg Med Chem in press.
• Efferth T, Lathan B, Volm M (1991) Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4. Br J Cancer 64: 87–89.
• Efferth T, Volm M (1992) Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother 9: 11–19.
• Efferth T, Volm M (1993) Modulation of P-glycoproteinmediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50: 303–308.
• Efferth T, Futscher BW, Osieka R (2001) 5-Azacytidine modulates the response of sensitive and multidrugresistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis 27: 637–648.
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498.
• Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171.
• Fardel O, Lecureur V, Guillouzo A (1996) The P-glycoprotein multidrug transporter. Gen Pharmacol 27: 1283–1291.
• Ferry DR, Malkhandi PJ, Russell MA, Kerr DJ (1995) Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49: 1851–1861.
• Ferte J (2000) Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267: 277–294.
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806–811.
• Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drugdrug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26: 802–811.
• FitzGerald DJ, Willingham MC, Cardarelli CO, Hamada H, Tsuruo T, Gottesman MM, Pastan I (1987) A monoclonal antibody — Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84: 4288–4292.
• Ford JM (1996) Experimental reversal of P-glycoproteinmediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991–1001.
• Fulda S, Susin SA, Kroemer G, Debatin KM (1998) Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58: 4453–4460.
• Gao Z, Gao Z, Fields JZ, Boman BM (1998) Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug-resistant human lung cancer cells. Anticancer Res 18: 3073–3076.
• Garcia-Chaumont C, Seksek O, Grzybowska J, Borowski E, Bolard J (2000) Delivery systems for antisense oligonucleotides. Pharmacol Ther 87: 255–277.
• Gardner SN (2002) Cell cycle phase-specific chemotherapy: computational methods for guiding treatment. Cell Cycle 1: 369–374.
• Gekeler V, Boer R, Ise W, Sanders KH, Schachtele C, Beck J (1995) The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 206: 119–126.
• Glazer RI (1998) The protein kinase ABC’s of signal transduction as targets for drug development. Curr Pharm Des 4: 277–290.
• Goldman B (2003) Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 95: 255–257.
• Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427.
• Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO, Pastan I (1994) Gene transfer of drug resistance genes. Implications for cancer therapy. Ann NY Acad Sci 716: 126–138.
• Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615–627.
• Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
• Griffith OW, Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254: 7558–7560.
• Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O’Brian CA (1996) Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 271: 2102–2111.
• Hagenbuch B, Gao B, Meier PJ (2002) Transport of xenobiotics across the blood-brain barrier. News Physiol Sci 17: 231–234.
• Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21–53.
• Hait WN, Choudhury S, Srimatkandada S, Murren JR (1993) Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J Clin Invest 91: 2207–2215.
• Hamada H, Tsuruo T (1986) Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785–7789.
• Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama K, Kurosawa Y, Tsuruo T (1990) Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein. Cancer Res 50: 3167–3171.
• Hannon GJ (2002) RNA interference. Nature 418: 244–251.
• Heike Y, Hamada H, Inamura N, Sone S, Ogura T, Tsuruo T (1990) Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells. Jpn J Cancer Res 81: 1155–1161.
• Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59: 2532–2535.
• Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K (1997) Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253–257.
• Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y, Akiyama S (1991) Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. Biochim Biophys Acta 1073: 309–315.
• Idriss HT, Hannun YA, Boulpaep E, Basavappa S (2000) Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say! J Physiol 524: 629–636.
• Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ (1996) Major vault protein LRPrelated multidrug resistance. Eur J Cancer 32A: 979–984.
• Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG (1999) Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 55: 761–769.
• Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988–994.
• Jin J, Wang FP, Wei H, Liu G (2005) Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 55: 179–188.
• Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97: 6775–6779.
• Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152–162.
• Kang H, Fisher MH, Xu D, Miyamoto YJ, Marchand A, Van Aerschot A, Herdewijn P, Juliano RL (2004) Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res 32: 4411–4419.
• Kawase M, Motohashi N (2003) New multidrug resistance reversal agents. Curr Drug Targets 4: 31–43.
• Kellen JA (2003) The reversal of multidrug resistance: an update. J Exp Ther Oncol 3: 5–13.
• Kim KH (2001) 3D-QSAR analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorg Med Chem 9: 1517–1523.
• Kitada S, Zapata JM, Andreeff M, Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393–397.
• Kitazono M, Okumura H, Ikeda R, Sumizawa T, Furukawa T, Nagayama S, Seto K, Aikou T, Akiyama S (2001) Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91: 126–131.
• Kobayashi H, Takemura Y, Wang FS, Oka T, Ohnuma T (1999) Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites. Int J Cancer 81: 944–950.
• Konig J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377–394.
• Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265–283.
• Krishna R, Mayer LD (2001) Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of
• selective MDR modulators. Curr Med Chem Anti-Canc Agents 1: 163–174.
• Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG (2001) MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33: 493–501.
• Lee CH (2004) Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem Anti-Canc Agents 4: 43–52.
• Lehne G (2000) P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 1: 85–99.
• Leung S, Bendayan R (1999) Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol 77: 625–630.
• Liscovitch M, Lavie Y (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349–355.
• Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997a) Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1361: 159–168.
• Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997b) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361: 169–176.
• Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011–2021.
• Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931–959.
• Lofgren C, Hjortsberg L, Blennow M, Lotfi K, Paul C, Eriksson S, Albertioni F (2004) Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells. Biochem Biophys Res Commun 320: 825–832.
• Loo TW, Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTSverapamil. J Biol Chem 276: 14972–14979.
• Lu X, Gong S, Monks A, Zaharevitz D, Moscow JA (2002) Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. J Exp Ther Oncol 2: 200–212.
• Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9: 319–336.
• Ma L, Krishnamachary N, Center MS (1995) Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338–3343.
• Maki N, Hafkemeyer P, Dey S (2003) Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278: 18132–18139.
• Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59: 4559–4563.
• Marbeuf-Gueye C, Salerno M, Quidu P, Garnier-Suillerot A (2000) Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 391: 207–216.
• Martin C, Berridge G, Higgins CF, Callaghan R (1997) The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br J Pharmacol 122: 765–771.
• Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128: 403–411.
• Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58: 624–632.
• Masuda Y, Kobayashi H, Holland JF, Ohnuma T (1998) Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother Pharmacol 42: 9–16.
• Matsumoto Y, Miyake K, Kunishio K, Tamiya T, Nagao S (2004) Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 51: 194–201.
• Mechetner EB, Roninson IB (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89: 5824– 5828.
• Minderman H, O’Loughlin KL, Pendyala L, Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10: 1826–1834.
• Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55: 425–461.
• Muller C, Laurent G, Ling V (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 163: 538–544.
• Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033–13037.
• Nagata J, Kijima H, Hatanaka H, Asai S, Miyachi H, Abe Y, Yamazaki H, Nakamura M, Watanabe N, Mine T, Kondo T, Scanlon KJ, Ueyama Y (2002) Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int J Oncol 21: 1021–1026.
• Naito M, Tsuge H, Kuroko C, Tomida A, Tsuruo T (1993a) Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16. Jpn J Cancer Res 84: 489–492.
• Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuta T, Heike Y, Tsuruo T (1993b) Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 85: 311–316.
• Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M (2002) ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8: 3767–3775.
• Ojima I, Bounaud PY, Oderd CF (1998) Recent strategies for the treatment of multi-drug resistance in cancer cells. Exp Opin Ther Patents 8: 1587–1598.
• Orlowski S, Garrigos M (1999) Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res 19: 3109–3123.
• Paddison PJ, Caudy AA, Hannon GJ (2002) Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 99: 1443–1448.
• Pakunlu RI, Cook TJ, Minko T (2003) Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 20: 351–359.
• Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486–4490.
• Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F (2001) A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61: 6034–6037.
• Phylactou LA (2001) Ribozyme gene therapy. Methods Mol Biol 175: 521–529.
• Pommerenke EW, Sinn H, Volm M (1995) Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin. Eur J Cancer 31A: 283–284.
• Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934–2949.
• Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1: 111–121.
• Regev R, Assaraf YG, Eytan GD (1999) Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 259: 18–24.
• Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M (1999) ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126: 681–688.
• Riordan JR, Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254: 12701–12705.
• Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46: 4805–4817.
• Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145–152.
• Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD (1998) Phase I and phar macokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964–2976.
• Sandor V, Fojo T, Bates SE (1998) Future perspectives for the development of P-glycoprotein modulators, in preparation. Drug Resist Updat 1: 190–200.
• Sato W, Yusa K, Naito M, Tsuruo T (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 173: 1252–1257.
• Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, Bates SE (1997) Pglycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 51: 1024–1033.
• Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ (2000) Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550–556.
• Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E (1993) N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268: 7474–7481.
• Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3–29.
• Scotto KW, Johnson RA (2001) Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv 1: 117–125.
• Secchiero P, Vaccarezza M, Gonelli A, Zauli G (2004) TNFrelated apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 10: 3673–3681.
• Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252–261.
• Seigneuret M, Garnier-Suillerot A (2003) A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J Biol Chem 278: 30115–30124.
• Senior AE, Bhagat S (1998) P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites. Biochemistry 37: 831–836.
• Senior AE, Gros P, Urbatsch IL (1998) Residues in P-glycoprotein catalytic sites that react with the inhibitor 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole. Arch Biochem Biophys 357: 121–125.
• Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168–2181.
• Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier- Borst W (1990) Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum B 17: 819–827.
• Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18: 78–83.
• Stefanska B, Dzieduszycka M, Martelli S, Tarasiuk J, Bontemps-Gracz M, Borowski E (1993) 6-[(aminoalkyl)amino]-substituted 7H-benzo[e]perimidin-7-ones as novel antineoplastic agents. Synthesis and biological evaluation. J Med Chem 36: 38–41.
• Stefanska B, Dzieduszycka M, Bontemps-Gracz MM, Borowski E, Martelli S, Supino R, Pratesi G, De Cesare M, Zunino F, Kusnierczyk H, Radzikowski C (1999) 8,11-Dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation. J Med Chem 42: 3494–3501.
• Stefanska B, Arciemiuk M, Bontemps-Gracz MM, Dzieduszycka M, Kupiec A, Martelli S, Borowski E (2003) Synthesis and biological evaluation of 2,7-dihydro-3Hdibenzo[de,h]cinnoline-3,7-dione derivatives, a novel group of anticancer agents active on a multidrug resistant cell line. Bioorg Med Chem 11: 561–572.
• Stefanska B, Bontemps-Gracz MM, Antonini I, Martelli S, Arciemiuk M, Piwkowska A, Rogacka D, Borowski E (2005) 2,7-Dihydro-3H-pyridazino[5,4,3-kl]acridin-3-one derivatives, novel type of cytotoxic agents active on multidrug-resistant cell lines. Synthesis and biological evaluation. Bioorg Med Chem 13: 1969–1975.
• Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL (1997) Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26: 77–100.
• Stewart AJ, Canitrot Y, Baracchini E, Dean NM, Deeley RG, Cole SP (1996) Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 51: 461–469.
• Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC, Shi Y (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515–5520.
• Szabo D, Keyzer H, Kaiser HE, Molnar J (2000) Reversal of multidrug resistance of tumor cells. Anticancer Res 20: 4261–4274.
• Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T (2001) Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces crossresistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 61: 172–177.
• Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450–458.
• Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H (2003) HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res 63: 6942–6947.
• Tarasiuk J, Frezard F, Garnier-Suillerot A, Gattegno L (1989) Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta 1013: 109–117.
• Tarasiuk J, Stefanska B, Plodzich I, Tkaczyk-Gobis K, Seksek O, Martelli S, Garnier-Suillerot A, Borowski E (2002) Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells. Br J Pharmacol 135: 1513–1523.
• Tarasiuk J, Majewska E, Seksek O, Rogacka D, Antonini I, Garnier-Suillerot A, Borowski E (2004) The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells. Biochem Pharmacol 68: 1815–1823.
• Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T (1992) Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383–20391.
• Teodori E, Dei S, Scapecchi S, Gualtieri F (2002) The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 57: 385–415.
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735–7738.
• Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10: 159–165.
• Tkaczyk-Gobis K, Tarasiuk J, Seksek O, Stefanska B, Borowski E, Garnier-Suillerot A (2001) Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells. Eur J Pharmacol 413: 131–141.
• Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD (2002) Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8: 670–678.
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972.
• Tsuruo T, Hamada H, Sato S, Heike Y (1989) Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 80: 627–631.
• Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94: 15–21.
• Van Dijk J, Tsuruo T, Segal DM, Bolhuis RL, Colognola R, van de Griend RJ, Fleuren GJ, Warnaar SO (1989) Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int J Cancer 44: 738–743.
• Vanhoefer U, Yin MB, Harstrick A, Seeber S, Rustum YM (1997) Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 53: 801–809.
• Vanhuyse M, Kluza J, Tardy C, Otero G, Cuevas C, Bailly C, Lansiaux A (2005) Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett 221: 165–175.
• van Zuylen L, Nooter K, Sparreboom A, Verweij J (2000) Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 18: 205–220.
• Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18: 2905–2917.
• Walder RY, Walder JA (1988) Role of RNase H in hybridarrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85: 5011–5015.
• Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T (1999) Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther 10: 1185–1195.
• Wang H, Chen XP, Qiu FZ (2003) Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J Gastroenterol 9: 1444–1449.
• Watanabe T, Naito M, Kokubu N, Tsuruo T (1997) Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 89: 512–518.
• Wielinga PR, Heijn M, Broxterman HJ, Lankelma J (1997) P-glycoprotein-independent decrease in drug accumulation by phorbol ester treatment of tumor cells. Biochem Pharmacol 54: 791–799.
• Wiese M, Pajeva IK (2001) Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8: 685–713.
• Wu H, Hait WN, Yang JM (2003) Small interfering RNAinduced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63: 1515–1519.
• Xu D, Ye D, Fisher M, Juliano RL (2002) Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther 302: 963–971.
• Yabuuchi H, Shimizu H, Takayanagi S, Ishikawa T (2001) Multiple splicing variants of two new human ATPbinding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 288: 933–939.
• Yang HH, Ma MH, Vescio RA, Berenson JR (2003) Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 21: 4239–4247.
• Yang JM, Vassil AD, Hait WN (2001) Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60: 674–680.
• Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454–462.
• Zeng H, Lin ZP, Sartorelli AC (2004) Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochem Pharmacol 68: 911–921.